---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061496"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:39:18.173481+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Synlogic Q3 net loss narrows to $12.1M; cash runway extended into H1 2025

## Summary
- Net loss of $12.1M ($2.57 per share) vs $17.9M ($3.73) in Q3 2022; revenue $0.4M from Roche collaboration.
- Closed $21M underwritten public offering and earned $2.5M Roche milestone, extending cash runway into H1 2025.
- Synpheny-3 pivotal trial in PKU on track: enrollment completion H2 2024, top-line data H1 2025.
- FDA granted Fast Track Designation for labafenogene marselecobac (SYNB1934) for PKU.
- Cash and investments $33.4M as of Sept 30, plus $19.6M net from October financing and $2.5M milestone.

## SEC filing metadata
- accession: 0000950170-23-061496
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000095017023061496/0000950170-23-061496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000095017023061496/sybx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061496
- JSON: https://secwatch.observer/filing/0000950170-23-061496.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061496.txt

## Key facts
- Earnings Releases
  SYNLOGIC, INC. reported the quarter ended September 30, 2023 results: revenue $0.4 million, net income $12.1 million, or $2.57 per share, EPS $2.57 per share.
  - Period: the quarter ended September 30, 2023
  - Revenue: $0.4 million
  - Net income: $12.1 million, or $2.57 per share
  - EPS: $2.57 per share
  - Result: reported results
  source text: $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration announced in November. Revenue for the three months ended September 30, 2023 was $0.4 million compared to $0.7 million for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527599/000095017023061496/0000950170-23-061496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.